Synthetic Stool a Prospective Treatment for C. difficile

Article

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

"A synthetic stool transplant has a lot of potential because we can control what goes in and we can alter, change, or modify it as necessary," says Elaine Petrof, an assistant professor in the Department of Medicine at Queen's University and in the Gastrointestinal Disease Research Unit (GIDRU) at Kingston General Hospital.

Petrof and her collaborator at the University of Guelph, Emma Allen-Vercoe, believe that a stool compound made from synthetic or "purified" bacteria could significantly improve on regular stool transplants. It could eliminate the chance of transmitting an infectious disease through fecal bacteria; physicians could tailor the mixture so as to increase patient acceptance; it would be easily reproducible; and, it may appeal to both doctors and patients as a 'cleaner' therapy.

Petrof and Dr. Allen Vercoe, an anaerobic microbiologist specializing in intestinal bacteria, are working closely to develop such a therapy. The goal behind their synthetic stool project is to offer a single-dose remedy, putting an end to revolving-door hospital visits for patients with recurring symptoms. Currently, they are continuing their research before using it as a new therapy.


 

Recent Videos
Meet Matthew Pullen, MD.
Clostridioides difficile  (Adobe Stock 260659307 by gaetan)
David Levine, PhD, DPT, MPH, FAPTA
Weekly Rounds with Infection Control Today
Henry Spratt, Infection Control Today's Editorial Advisory Board member
DEBORAH BIRX, MD, is a retired Army Colonel and Global Ambassador to 3 US presidents, Birx has over 40 years of experience fighting global pandemics. Her research and work have been credited with saving over 22 million lives in Africa through the PEPFAR program, and she has authored over 200 academic publications.
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Related Content